Catheter Precision announced that at the recently held European Society of Cardiology Symposium, interim results demonstrating the use of VIVO in localizing the site of origin of ventricular tachycardia for patients with scar related re-entrant VT were presented. Additionally, the presentation showed the relationship to the relevant myocardial scar on cross-sectional imaging from the CT scan. The study, ongoing at the Warwick Medical School at the University Hospitals of Coventry and Warwickshire is ongoing with lead investigator Professor Tarv Dhanjal. The presentation was entitled “Accuracy of a non-invasive mapping system for the localization of re-entrant VT site of origin and its relationship to myocardial scar on cross-sectional imaging”. The interim results were presented on twenty patients with structural heart disease and a mean ejection fraction of 35.5 and included patients with ischemic cardiomyopathy, dilated cardiomyopathy, and hypertrophic cardiomyopathy. The results showed a VIVO accuracy of 90% as compared to invasive mapping, performed with the Abbott Advisor HD Grid multipolar catheter. VIVO non-invasive mapping showed a significant match especially in the area of myocardial scar in these patients. At a mean follow up of seven months, procedural success has been noted in 90% of the patients.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VTAK:
- Catheter Precision reports LockeT purchase order in greater Chicago area
- Catheter Precision reports Q2 EPS ($5.57) vs. ($2.94) last year
- Catheter Precision announces publication of LockeT data
- Catheter Precision Converts Series A Preferred Stock
- Catheter Precision completes enrollment of 75 patients in LockeT-II study